Cullinan Therapeutics, Inc. - 8-K Filing
Cullinan Therapeutics initiates NDA submission for zipalertinib in first-line treatment of EGFR exon 20 insertion NSCLC under FDA's RTOR program. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CGEM